Transgene – Preclinical Results Showing TG6050, a Novel Oncolytic Virus, induces Tumor Regression by Activating Innate and Adaptive immune responses presented at AACRPreclinical results showing TG6050 induces tumor regression by activating innate and adaptive immune responses15